ML
Therapeutic Areas
Schrodinger Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MALT1 Inhibitor | Oncology (Lymphomas) | Phase 1 |
| CDC7 Inhibitor | Oncology (Solid Tumors) | Preclinical |
| SOS1::KRAS Inhibitor | Oncology (KRAS-driven cancers) | Discovery/Preclinical |
| Wee1 Inhibitor | Oncology | Preclinical |
Leadership Team at Schrodinger
RF
Ramy Farid, Ph.D.
President and CEO, Board Member
RA
Robert Abel, Ph.D.
Executive Vice President, Chief Scientific Officer, Platform
KA
Karen Akinsanya, Ph.D.
President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships
MA
Mannix Aklian
Executive Vice President, Chief Commercial Officer, Global Head of Software Sales and Marketing
RJ
Richie Jain
Chief Financial Officer
PL
Patrick Lorton
Executive Vice President, Chief Technology Officer and Chief Operating Officer, Software
JM
Jaren Madden
Chief Corporate Affairs Officer and Head of Investor Relations
RA
Richard A. Friesner
Co-founder, Board Member, and Scientific Advisory Chairman